Session: SUN 624-646-Growth: Clinical Trials & Observational Studies
Poster Board SUN-643
Methods: Areal BMD (by DXA) was measured in 25 IGHD (13 males, 38.2±12.2 yrs, 129±10.7 cm) and 22 controls (CO) (9 males, 38.9±10.4 yrs, 163±9.8 cm). vBMD was calculated with the formula: BMDL1-L4/√Area L1-L4. Joint function was assessed by goniometry of elbow, hips and knees. X rays were used to measure the anatomic axis of knee and the severity of OA, defined by an adaptation of the Osteoarthritis Research Society International classification that accounts for joint space narrowing or osteophytes scores in the knees and hip. Student’s t test was used to compare groups.
Results: Height and weight standard deviation scores were lower in IGHD than CO (-6.47±1.52 vs. -0.98±0.89, p<0.0001 and -5.26±3.05 vs. 0.4±1.03, p<0.0001 respectively). Areal BMD (g/cm2) was lower in IGHD than CO at L1-L4 (0.94± 0.13 vs. 1.20±0.11, p = 0.0001) and total femur (0.91±0.09 vs. 1.05±0.14, p=0.0001) but vBMD (g/cm3) was similar in the two groups (0.16±0.03 vs. 0.16±0.02, p=0.953). Range of motion was similar in elbow, knee and hip in IGHD and CO. Limitation of extension of the elbow was found in 1 IGHD individual and in none of controls. Genu valgum was more frequent in IGHD than CO (9/23 vs. 1 /15, p<0.0001). OA knee score was similar and hip score was higher in IGHD than CO (1.73±0.36 vs. 0.74±0.11, p=0.003)
Discussion: Although adult GH-naïve individuals with congenital IGHD have lower areal BMD, they have normal vBMD (more appropriate technique to compare different sized subjects). Our data of normal vBMO in IGHD (of both genders) agree with a previous report in 4 males with a different GHRH-R mutation (2), and with data from subjects with GH resistance (3), suggesting that bone density is not reduced in lifetime congenital IGHD. In contrast, the IGHD subjects present more OA and genu valgum than CO.
Conclusion: Congenital, lifetime IGHD causes joint problems, reduces bone size but does not reduce vBMD.
Nothing to Disclose: CEE, GMFS, RS, JAMS, FAP, CRPO, AHOS, EGS, VCC, RMCP, EHOV, FJAD, TVR, MHA
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters